Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

Published July 12, 2026 · Category: Finance

Overview

William Guyer, chief development officer, reported a sale of 20,000 shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) on July 7, 2026, according to an SEC Form 4 filing.

Corcept Therapeutics is a specialized pharmaceutical company that maintains a focused commercial strategy centered on its lead therapeutic asset, Korlym, which addresses a significant unmet medical need in the treatment of endogenous Cushing's syndrome. With 730 employees and operations headquartered in Menlo Park, California, Corcept has demonstrated strong market performance, with its stock appreciating 39% over the past year, reflecting investor confidence in its pipeline and commercial execution.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• You don’t have to be rich to be financially independent. Here’s how to take control of your money.
• 1 Big Reason to Buy FuelCell Energy Stock While It's Still Under $30
• A Galicia Director Just Bought $2.1 Million in Stock Despite a 66% Profit Drop